Colorectal Cancer Dataset in Xijing Hospital From 2011

March 11, 2024 updated by: Xijing Hospital
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

40000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shaanxi
      • Xi'an, Shaanxi, China
        • Recruiting
        • Fourth Military Medical University
        • Contact:
          • Jipeng Li
          • Phone Number: +86-029-84771533

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Colorectal cancer patients mainly comes from the western areas of China, and would accept the surgical procedures. Participate would be followed up every 6 months after surgery.

Description

Inclusion Criteria:

  • 1. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
  • 2. Visit our center with complete medical records and pathological information;
  • 3. Colorectal cancer patients diagnosed between 2013 and 2023.

Exclusion Criteria:

  • 1. The patient has other colorectal malignancies other than adenocarcinoma;
  • 2. Malignant tumors adjacent to organs invading the colon and rectum;
  • 3. Malignant tumors from distant organs metastasize to the colon and rectum;
  • 4. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
colorectal cancer
Colorectal cancer patients are enrolled when patients were underwent surgeries.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
overall survival
Time Frame: from date of diagnosis until the date of death from any cause, assessed up to 120 months
to dead or lost to follow
from date of diagnosis until the date of death from any cause, assessed up to 120 months
DFS
Time Frame: from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months
disease-free survival
from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xijing Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2011

Primary Completion (Estimated)

January 1, 2048

Study Completion (Estimated)

January 1, 2048

Study Registration Dates

First Submitted

February 18, 2024

First Submitted That Met QC Criteria

March 11, 2024

First Posted (Actual)

March 13, 2024

Study Record Updates

Last Update Posted (Actual)

March 13, 2024

Last Update Submitted That Met QC Criteria

March 11, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CRC dataset

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The investigators aim to explore the clinical characteristics of colorectal cancer patients in the Xijing hospital.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chemotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe